news
Cellistic and Celyad Oncology announce GMP cell therapy manufacturing operations transaction
Cellistic has agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for €6 million.
List view / Grid view
Chimeric Antigen Receptors (CARs)
news
Blocking trogocytosis improves ability of CAR T-cell therapy to treat cancer in mice
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
news
Combining immunotherapy and virotherapy shows promise for treatment-resistant cancers
The study describes how oncolytic virotherapy can work with existing immunotherapy techniques, boosting the immune capacity to effectively target and destroy cancer cells.
news
Researchers halt the growth of multiple myeloma in mice
Scientists from Stanford University have been able to halt the growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3.
news
Research shows that EBAG9 leads to strengthened immune response to cancer
The scientists say that shutting down the EBAG9 gene allows the body to destroy tumour cells earlier and more radically.
news
Discovered receptor that could alleviate the need for chemotherapy
Researchers have shown that a synthetic IL-9 receptor allows T cells to fight against cancer without the need for chemotherapy or radiation.
news
Global team aims to bring next generation CAR T-cell therapies to children with solid tumours
The Mark Foundation for Cancer Research awards ~$12 million to Cancer Grand Challenges Team to develop new immunotherapies for childhood solid tumours.
whitepaper
Application note: Advancing CAR T-cell therapy with CTS TrueCut Cas9 Protein
Read this free application note where we look at the CTS TrueCut Cas9 Protein, from its detailed quality specifications to its performance in primary T cells.
news
Immunity boosting treatment enhances CAR T-cell therapy for blood cancers
A new study in mice has shown blood cancer treatment with protein interleukin-7 revs up T-cell immunotherapy.
news
Novel CRISPR screen revealed loss of genes in the interferon gamma receptor signalling pathway
A new study has highlighted that the interferon gamma receptor pathway is necessary for CAR T-cell mediated killing in solid tumours.
news
New research could bring life-saving benefits of CAR T therapy to AML patients
Researchers have developed a novel method for enhancing CAR T therapy through a drug combination and cellular engineering that improves the strength and durability of the tumour-killing effect of a CAR T directed against AML.
news
A new target for CAR T cells in solid tumours
In a new study, researchers have shared the identification of a new potential target for CAR T cells that inhibits growth in lung and ovarian tumours.
article
How to develop the next generation of CAR T-cell therapies
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…
news
Novel CAR T-cell therapy for B-cell cancers shows promise in vivo
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
news
RN7SL1 RNA shown to activate T cells to fight against cancer
A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.